Literature DB >> 25953461

A role for epigenetics in the formation of chromosome translocations in acute leukemia.

Heidi J Gill Super1.   

Abstract

In general, the field of cancer genetics seems to have shifted its focus from cancer-associated genes to cancer-associated epigenetic activity. An abundance of evidence suggests that epigenetic malfunction, such as aberrant histone modification, and altered DNA methylation, is at the root of much, if not most aberrant gene expression associated with cancer. However, a role for epigenetics in physical DNA changes, such as chromosome rearrangements, is less obvious, and certainly less well understood. A growing body of evidence suggests that epigenetics may play a role in many of the steps of aberrant chromosome recombination, especially chromosome translocations, associated with cancers such as acute leukemias.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute Leukemia; Chromosome translocations; Epigenetics; Etoposide; Nucleosome

Mesh:

Substances:

Year:  2015        PMID: 25953461      PMCID: PMC5123567          DOI: 10.1016/j.cancergen.2015.03.006

Source DB:  PubMed          Journal:  Cancer Genet


  34 in total

1.  Dynamics of DNA double-strand breaks revealed by clustering of damaged chromosome domains.

Authors:  Jacob A Aten; Jan Stap; Przemek M Krawczyk; Carel H van Oven; Ron A Hoebe; Jeroen Essers; Roland Kanaar
Journal:  Science       Date:  2004-01-02       Impact factor: 47.728

Review 2.  Chromosomal domains: epigenetic contexts and functional implications of genomic compartmentalization.

Authors:  Amos Tanay; Giacomo Cavalli
Journal:  Curr Opin Genet Dev       Date:  2013-02-14       Impact factor: 5.578

Review 3.  Etoposide and illegitimate DNA double-strand break repair in the generation of MLL translocations: new insights and new questions.

Authors:  P A Sung; J Libura; C Richardson
Journal:  DNA Repair (Amst)       Date:  2006-06-30

4.  Model for MLL translocations in therapy-related leukemia involving topoisomerase IIβ-mediated DNA strand breaks and gene proximity.

Authors:  Ian G Cowell; Zbyslaw Sondka; Kayleigh Smith; Ka Cheong Lee; Catriona M Manville; Malgorzata Sidorczuk-Lesthuruge; Holly Ashlene Rance; Kay Padget; Graham Hunter Jackson; Noritaka Adachi; Caroline A Austin
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-21       Impact factor: 11.205

Review 5.  SWI/SNF nucleosome remodellers and cancer.

Authors:  Boris G Wilson; Charles W M Roberts
Journal:  Nat Rev Cancer       Date:  2011-06-09       Impact factor: 60.716

6.  Biased distribution of chromosomal breakpoints involving the MLL gene in infants versus children and adults with t(4;11) ALL.

Authors:  M Reichel; E Gillert; S Angermüller; J P Hensel; F Heidel; M Lode; T Leis; A Biondi; O A Haas; S Strehl; E R Panzer-Grümayer; F Griesinger; J D Beck; J Greil; G H Fey; F M Uckun; R Marschalek
Journal:  Oncogene       Date:  2001-05-24       Impact factor: 9.867

7.  Mediator, TATA-binding protein, and RNA polymerase II contribute to low histone occupancy at active gene promoters in yeast.

Authors:  Suraiya A Ansari; Emily Paul; Sebastian Sommer; Corinna Lieleg; Qiye He; Alexandre Z Daly; Kara A Rode; Wesley T Barber; Laura C Ellis; Erika LaPorta; Amanda M Orzechowski; Emily Taylor; Tanner Reeb; Jason Wong; Philipp Korber; Randall H Morse
Journal:  J Biol Chem       Date:  2014-04-11       Impact factor: 5.157

8.  The SWR1 histone replacement complex causes genetic instability and genome-wide transcription misregulation in the absence of H2A.Z.

Authors:  Macarena Morillo-Huesca; Marta Clemente-Ruiz; Eloísa Andújar; Félix Prado
Journal:  PLoS One       Date:  2010-08-12       Impact factor: 3.240

9.  The MLL recombinome of acute leukemias in 2013.

Authors:  C Meyer; J Hofmann; T Burmeister; D Gröger; T S Park; M Emerenciano; M Pombo de Oliveira; A Renneville; P Villarese; E Macintyre; H Cavé; E Clappier; K Mass-Malo; J Zuna; J Trka; E De Braekeleer; M De Braekeleer; S H Oh; G Tsaur; L Fechina; V H J van der Velden; J J M van Dongen; E Delabesse; R Binato; M L M Silva; A Kustanovich; O Aleinikova; M H Harris; T Lund-Aho; V Juvonen; O Heidenreich; J Vormoor; W W L Choi; M Jarosova; A Kolenova; C Bueno; P Menendez; S Wehner; C Eckert; P Talmant; S Tondeur; E Lippert; E Launay; C Henry; P Ballerini; H Lapillone; M B Callanan; J M Cayuela; C Herbaux; G Cazzaniga; P M Kakadiya; S Bohlander; M Ahlmann; J R Choi; P Gameiro; D S Lee; J Krauter; P Cornillet-Lefebvre; G Te Kronnie; B W Schäfer; S Kubetzko; C N Alonso; U zur Stadt; R Sutton; N C Venn; S Izraeli; L Trakhtenbrot; H O Madsen; P Archer; J Hancock; N Cerveira; M R Teixeira; L Lo Nigro; A Möricke; M Stanulla; M Schrappe; L Sedék; T Szczepański; C M Zwaan; E A Coenen; M M van den Heuvel-Eibrink; S Strehl; M Dworzak; R Panzer-Grümayer; T Dingermann; T Klingebiel; R Marschalek
Journal:  Leukemia       Date:  2013-04-30       Impact factor: 11.528

10.  Nonreciprocal chromosomal translocations in renal cancer involve multiple DSBs and NHEJ associated with breakpoint inversion but not necessarily with transcription.

Authors:  Hanif Ali; Angelika Daser; Paul Dear; Henry Wood; Pamela Rabbitts; Terence Rabbitts
Journal:  Genes Chromosomes Cancer       Date:  2013-01-23       Impact factor: 5.006

View more
  3 in total

1.  The expression and regulation of HOX genes and membrane proteins among different cytogenetic groups of acute myeloid leukemia.

Authors:  Huili Wang; Sheng-Yan Lin; Fei-Fei Hu; An-Yuan Guo; Hui Hu
Journal:  Mol Genet Genomic Med       Date:  2020-07-02       Impact factor: 2.183

2.  The landscape of DNA methylation-mediated regulation of long non-coding RNAs in breast cancer.

Authors:  Chunlong Zhang; Xinyu Wang; Xuecang Li; Ning Zhao; Yihan Wang; Xiaole Han; Ce Ci; Jian Zhang; Meng Li; Yan Zhang
Journal:  Oncotarget       Date:  2017-05-08

Review 3.  LncRNAs as Chromatin Regulators in Cancer: From Molecular Function to Clinical Potential.

Authors:  Rodiola Begolli; Nikos Sideris; Antonis Giakountis
Journal:  Cancers (Basel)       Date:  2019-10-10       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.